

STATISTICAL ANALYSIS PLAN

[REDACTED]

[REDACTED]

[REDACTED]

A Randomized, Blinded, No-Treatment Control, Multicenter, Prospective Clinical Study of TEOSYAL® RHA Redensity for the Treatment of Moderate to Severe Perioral Rhytids

Study Sponsor:

TEOXANE SA

Rue de Lyon 105

CH - 1203 Genève, Switzerland

+41 (0) 22 344 96 36

Clinical Research Organization:

[REDACTED]

Confidentiality Statement

The information contained in this document is provided in confidence. It is understood that this information will not be disclosed to others without prior agreement with the Sponsor, except to other study personnel and to the extent necessary to obtain informed consent from participating subject.

SAP APPROVAL SIGNATURE PAGE

The following individuals approve this version of the TEO-RHA-1501 Statistical Analysis Plan.

Accepted for the Sponsor – TEOXANE SA:

_____ Printed Name	_____ Title
_____ Signature	_____ Date

Accepted for the Clinical Research Organization - [REDACTED].:

_____ Printed Name	_____ Title
_____ Signature	_____ Date

TABLE OF CONTENTS

SAP APPROVAL SIGNATURE PAGE	2
TABLE OF CONTENTS	3
ABBREVIATIONS	5
1. INTRODUCTION	6
1.1 Background	6
1.2 Hypothesis	6
1.3 Primary Objectives	6
2. OVERVIEW OF STUDY DESIGN	7
2.1 Study Design	7
2.2 Sample Size	7
3. STUDY POPULATION	10
3.1 Inclusion Criteria	10
3.2 Exclusion Criteria	10
4. TREATMENT ALLOCATION AND RANDOMIZATION	11
5. DEVICE APPLICATION	12
5.1 Initial Treatment (V1)	12
5.2 Touch-up Treatment (V2; Week 2)	12
5.3 Optional Early Retreatment (V5, 6, 7, or 8; Weeks 12, 16, 24 or 36)	12
5.4 Retreatment (V9; Week 52)	13
6. STUDY EVALUATIONS	13
6.1 Efficacy Variables	13
6.2 Safety Variables	15
6.2.1 Common Treatment Response (CTR) Diary	15
6.2.2 Assessment of Injection Site Pain	15
6.2.3 Lip Functionality	15
6.2.4 Adverse Events (AEs)	15
6.2.5 Concomitant Medications and Procedures	15
7. ANALYSIS POPULATIONS	15
7.1 Populations	16
7.1.1 Intent-to-Treat (ITT) Population	16
7.1.2 Per Protocol (PP) Population	16
7.1.2.1 Safety (SAFT) Population	16
8. SAMPLE SIZE JUSTIFICATION	17
9. STATISTICAL METHODS	17
9.1 Efficacy Analyses	17
9.1.1 Primary Endpoint	17
9.1.2 Secondary Endpoints	18
9.1.3 Exploratory Endpoints	18
9.2 Safety Analyses	20
9.2.1 Adverse Events (AEs)	20
9.2.2 Injection Site Pain	20

9.2.3	Lip Functionality	21
9.2.4	Common Treatment Responses (CTRs)	21
9.2.5	Concomitant Medications and Procedures	21
9.3	General Statistical Considerations	21
9.3.1	Statistical Testing	21
9.3.2	Comparison of Treatment Groups	21
9.3.3	Descriptive Statistics	21
9.3.4	Missing Values	22
9.3.5	Discontinuation and Drop-Outs	22
9.3.6	Multiple Comparisons	22
9.3.7	Multicenter Data	22
9.3.8	Pooling of Data from US and Canadian Sites	22
9.3.9	Visit Windows	23
9.3.10	Dates	23
9.3.11	Interim Analysis	23
9.3.12	Outliers	23
9.3.13	Software Documentation	23
APPENDIX A: SUMMARY OF STATISTICAL TESTS.....		24
APPENDIX B: STATISTICAL TABLES		35

A [REDACTED]

1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100

1. INTRODUCTION

This statistical analysis plan (SAP) gives a comprehensive and detailed description of statistical techniques to be used [REDACTED]. The purpose of this SAP is to ensure the credibility of the study findings by pre-specifying the statistical approaches for the analysis of study data prior to database lock. This SAP provides additional details concerning the statistical analyses outlined in the protocol. Whenever differences exist in descriptions or explanations provided in the protocol and SAP, the SAP prevails.

1.1 Background

Hyaluronic acid (HA) is a long-chain, repeated dimer, N-acetyl glucosamine and D-glucuronic acid polymer and is a major component of the extracellular matrix. HA is widely present in all animal species and does not differ from one species to another. Due to this extended compatibility, HA can be used in humans without unacceptable adverse effects. Due to its natural viscoelastic and hydrogel properties, HA is widely used as matrix in tissue regeneration and particularly in dermal defect reconstruction.

TEOSYAL® RHA Redensity dermal filler is a device containing colorless, biodegradable, sterile, biocompatible, crosslinked HA of non-animal origin (i.e., bacterial fermentation using *Streptococcus zooepidemicus*). Crosslinking is performed using 1,4-butanediol diglycidyl ether (BDDE) to form a gel. The formulation also contains 0.3% w/w of lidocaine hydrochloride. TEOSYAL® RHA Redensity is an investigational device that has not yet been approved by the FDA. In the current study, this device will be compared to a No-Treatment control in a superiority pivotal study designed to support a PMA application for TEOSYAL® RHA Redensity.

1.2 Hypothesis

TEOSYAL® RHA Redensity will be superior to No-Treatment control for the correction of moderate to severe perioral rhytids as determined by the PR-SRS at Week 8 after the last treatment. An improvement in the PR-SRS of ≥ 1 -grade compared to pre-treatment will be considered clinically meaningful.

1.3 Primary Objectives

The study's primary objectives are to establish the safety and effectiveness of TEOSYAL® RHA Redensity in the treatment of moderate to severe perioral rhytids:

1. To demonstrate the superiority of TEOSYAL® RHA Redensity versus the No-Treatment control at 8 weeks for the correction of moderate to severe perioral rhytids. Assessment of superiority will be based on the Perioral Rhytids Severity Rating Scale (PR-SRS) as rated by the Blinded Live Evaluator (BLE).

To evaluate the safety of TEOSYAL® RHA Redensity for the treatment of moderate to severe perioral rhytids. Safety will be determined by the rates of Adverse Events (AEs) associated with the use of the study device. Subjects will be observed for up to approximately 52 weeks following initial treatment or touch-up treatment with the study device. Safety will also be evaluated for 4 weeks following any retreatment.

2 OVERVIEW OF STUDY DESIGN

2.1 Study Design

This is a randomized, blinded, No-Treatment control, multicenter, prospective clinical study.

The **Treating Investigator** (TI) will evaluate subjects for eligibility of the subject for the study. The **Blinded Live Evaluator** (BLE) at screening will evaluate the subject's perioral rhytids severity using the Perioral Rhytids Severity Rating Scale (PR-SRS) in order to confirm eligibility and to establish a pre-treatment score. This will be done independently of the TI, and exact concordance between the BLE and the TI is not necessary.

Enrolled subjects will be randomized to either the TEOSYAL® RHA Redensity treatment group or the "No-Treatment" control group. The TI will administer study device, and if necessary, subjects will receive a touch-up treatment 14 days following the initial treatment to optimize the results. The TI will conduct safety and effectiveness evaluations at study subject visits, which will occur at Week 4, 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment, and 4 weeks after a repeat treatment.

The BLE will conduct assessments of efficacy during the trial, including assessment of the primary endpoint at Week 8 after initial or touch up treatment. The BLE will conduct effectiveness evaluations at Week 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment.

Subjects will be followed for 52 weeks from initial or touch up treatment, at which point they will be offered a repeat treatment (provided that the TI deems the treatment to be appropriate, and if the subject agrees). The subject will then be followed for an additional 4 weeks after the treatment before exiting the study.

Should a subject return to his/her pre-treatment PR-SRS level before Week 52, as assessed by the TI, he/she will be eligible to receive an early repeat treatment (provided that the TI deems the treatment to be appropriate, and if the subject agrees) at Week 12, or Week 16, or Week 24, or Week 36 after initial or touch-up treatment. .

Subjects randomized to the "No-Treatment" control group will receive their first treatment after the primary endpoint evaluation (8 weeks after randomization) and will then follow the same schedule as the initial treatment group.

2.2 Sample Size



[illegible]

	Overall Performance Metrics											
	Q1 Performance				Q2 Performance				Q3 Performance			
	Target	Actual	Variance	Trend	Target	Actual	Variance	Trend	Target	Actual	Variance	Trend
Revenue	1000	1050	+50	Up	1100	1150	+50	Up	1200	1250	+50	Up
Profit	500	520	+20	Stable	550	580	+30	Up	600	630	+30	Up
Customer Satisfaction	85	88	+3	Up	88	90	+2	Stable	90	92	+2	Up
Employee Engagement	75	78	+3	Up	78	80	+2	Stable	80	82	+2	Up
Market Share	15%	16%	+1%	Up	16%	17%	+1%	Stable	17%	18%	+1%	Up
Operational Efficiency	90	92	+2	Up	92	94	+2	Stable	94	96	+2	Up
Product Quality	95	96	+1	Stable	96	97	+1	Up	97	98	+1	Stable
Customer Retention	80	82	+2	Up	82	84	+2	Stable	84	86	+2	Up
Employee Turnover	10%	9%	-1%	Down	9%	8%	-1%	Down	8%	7%	-1%	Down
Compliance Score	98	99	+1	Stable	99	100	+1	Up	100	100	0	Stable
Brand Awareness	70	72	+2	Up	72	74	+2	Stable	74	76	+2	Up
Supply Chain Reliability	88	90	+2	Up	90	92	+2	Stable	92	94	+2	Up
Customer Acquisition	120	130	+10	Up	130	140	+10	Up	140	150	+10	Up
Employee Training Completion	90	92	+2	Up	92	94	+2	Stable	94	96	+2	Up
Product Innovation Pipeline	80	82	+2	Up	82	84	+2	Stable	84	86	+2	Up
Customer Feedback Response Time	24h	22h	-2h	Down	22h	20h	-2h	Down	20h	18h	-2h	Down
Employee Safety Incidents	5	4	-1	Down	4	3	-1	Down	3	2	-1	Down
Market Research Accuracy	92	94	+2	Up	94	96	+2	Stable	96	98	+2	Up
Customer Loyalty Program Effectiveness	85	87	+2	Up	87	89	+2	Stable	89	91	+2	Up
Employee Performance Review Score	78	80	+2	Up	80	82	+2	Stable	82	84	+2	Up
Product Launch Success Rate	90	92	+2	Up	92	94	+2	Stable	94	96	+2	Up
Customer Churn Rate	12%	11%	-1%	Down	11%	10%	-1%	Down	10%	9%	-1%	Down
Employee Onboarding Time	30 days	28 days	-2 days	Down	28 days	26 days	-2 days	Down	26 days	24 days	-2 days	Down
Product Defect Rate	0.5%	0.4%	-0.1%	Down	0.4%	0.3%	-0.1%	Down	0.3%	0.2%	-0.1%	Down
Customer Service Score	88	90	+2	Up	90	92	+2	Stable	92	94	+2	Up
Employee Retention Rate	90%	92%	+2%	Up	92%	94%	+2%	Stable	94%	96%	+2%	Up
Product Quality Improvement	85	87	+2	Up	87	89	+2	Stable	89	91	+2	Up
Customer Satisfaction Score	85	88	+3	Up	88	90	+2	Stable	90	92	+2	Up
Employee Engagement Score	75	78	+3	Up	78	80	+2	Stable	80	82	+2	Up
Market Share Growth	15%	16%	+1%	Up	16%	17%	+1%	Stable	17%	18%	+1%	Up
Operational Efficiency Score	90	92	+2	Up	92	94	+2	Stable	94	96	+2	Up
Product Quality Score	95	96	+1	Stable	96	97	+1	Up	97	98	+1	Stable
Customer Retention Rate	80	82	+2	Up	82	84	+2	Stable	84	86	+2	Up
Employee Turnover Rate	10%	9%	-1%	Down	9%	8%	-1%	Down	8%	7%	-1%	Down
Compliance Score	98	99	+1	Stable	99	100	+1	Up	100	100	0	Stable
Brand Awareness Score	70	72	+2	Up	72	74	+2	Stable	74	76	+2	Up
Supply Chain												

3. STUDY POPULATION

The study population includes female and male subjects with at least 25% of the population of Fitzpatrick skin IV to VI subjects.

3.1 Inclusion Criteria

1. Outpatient, male or female of any race, 22 years of age or older. Female subjects of childbearing potential must have a negative UPT at Visit 1 and practice a reliable method of contraception throughout the study.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

4. Be able to follow study instructions and likely to complete all required visits;
5. Sign the IRB-approved ICF, Photographic Release Form and the Authorization for Use and release of Health and Research Study Information (HIPAA) form prior to any study-related procedures being performed.

3.2 Exclusion Criteria

1. Female subjects that are pregnant, breast-feeding, or of childbearing potential and not practicing reliable birth control.

[REDACTED]

3. Use of a prohibited treatment/procedure within time periods [REDACTED]

[REDACTED]

5. Known susceptibility to keloid formation, hypertrophic scarring or clinically significant skin pigmentation disorders (TI discretion).

7. History of active chronic debilitating systemic disease that in the opinion of the investigator, would make the subject a poor candidate in the study.

9. Malignancy (excluding non-melanoma skin cancer) within the past 5 years.

11. History or presence of condition or feature that may confound the interpretation of the results in the perioral region, for example, tattoo, significant facial hair, acne scarring, prior surgery in the area, potential for active disease or infection flare up such as herpes simplex.

13. History of skin cancer in the treatment area.

15. Clinically active disease or infection in the perioral area or mouth (e.g., dental abscess).

17. Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results or compliance of the subject and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study (TI discretion).

19. Subjects seeking lip augmentation.

21. Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.

4. TREATMENT ALLOCATION AND RANDOMIZATION

Upon qualifying for treatment, subjects will be randomized to a study group utilizing a randomization algorithm embedded into the electronic Case Report Form (eCRF). Subjects will be randomized (3:1 ratio) to one of the following groups:

- TEOSYAL® RHA Redensity;
- No-Treatment (untreated control).

Subjects will be considered “enrolled” at the time of consent, and will be considered “enrolled and randomized” at the time of randomization. The required sample size is based on “enrolled and

randomized” subjects. If an enrolled subject withdraws from the study prior to being randomized, he/she may be replaced.

[REDACTED]

5. DEVICE APPLICATION

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

subject agrees. The subject will then be followed for an additional 4 weeks before exiting the study.

6. STUDY EVALUATIONS

6.1 Efficacy Variables

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6.2 Safety Variables

6.2.1 Common Treatment Response (CTR) Diary

Subjects will record their observations of CTRs for the first 14 days after each treatment (initial, touch-up, retreatment(s)). The CTRs to be assessed are redness, pain, tenderness, firmness, swelling, lumps/bumps, bruising, itching, discoloration, and “other” (e.g., fever, headache, changes in vision). The presence and the severity of each observed sign/symptom will be recorded as none, mild, moderate, or severe.

CTRs will also be considered as Adverse Events if the duration and/or severity are in excess of that typically observed following injection of a dermal filler, and are clinically significant as determined by the Tx Investigator. Importantly, CTRs persisting longer than 14 days and CTRs that are indicated on the last recorded day of the CTR Diary, will be recorded as AEs regardless of severity or clinical significance.

6.2.2 Assessment of Injection Site Pain

Subjects will assess injection site pain (during injection and post-injection) using a 100mm Visual Analog Scale (VAS).

6.2.3 Lip Functionality

Lip functionality testing will include the following Yes/No evaluations:

- Lip function: Yes or No with the following question: “Can the subject drink/suck through a straw effectively?”
- Lip Sensation:
 1. monofilament test (i.e., three points on the upper lip and three points on the lower lip);
 2. cotton wisp test (i.e., three points on the upper lip and three points on the lower lip).
- Lip Movement: Yes or No with the following question and based on a list of 10 words, “Can the subject effectively pronounce the following words?”

6.2.4 Adverse Events (AEs)

The Treating Investigator will assess AEs and record details of seriousness, severity, duration, and action taken with the study device, and relationship to the study device. AEs will be reported from the time of consent until the final visit, or to 1 month following the last treatment.

6.2.5 Concomitant Medications and Procedures

Any medication or procedure (including OTC preparations) that the subject takes during the study protocol period will be considered concomitant medication and will be recorded.

7. ANALYSIS POPULATIONS

7.1 Populations

Three analysis populations will be defined: Intent-to-Treat (ITT), Per Protocol (PP), and Safety (SAFT). All populations will be defined and determined prior to unblinding for the final analysis.

7.1.1 Intent-to-Treat (ITT) Population

[REDACTED]

7.1.2 Per Protocol (PP) Population

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

7.1.2.1 Safety (SAFT) Population

The SAFT Population will consist of all subjects in the No-Treatment control group, and all subjects in the Redensity treatment group that are randomized and received at least one treatment with a study device. Subjects in the SAFT Population will be analyzed in the group of the treatment they actually received, whether or not it is the group to which they are randomized.

8. SAMPLE SIZE JUSTIFICATION

[REDACTED]

The study will ensure that enrolled subjects are representative of U.S. population ethnicity and will be comprised of at least 25% subjects of Fitzpatrick skin IV to VI. In order to be able to detect a sufficient AE rate (i.e., maximum 2.5% in the sub-population of subjects of Fitzpatrick skin type IV to VI), the number of subjects must be increased beyond that required for achieving statistical power for the primary efficacy outcome; specifically:

[REDACTED]

[REDACTED]

[REDACTED]

9. STATISTICAL METHODS

9.1. Efficacy Analyses

[REDACTED]

9.1.1 Primary Endpoint

The primary endpoint will be a co-primary endpoint. A responder will be defined as a subject who has a ≥ 1 -grade improvement on the **PR-SRS** as assessed by the **BLE** at Week 8 after initial or touch-up treatment, compared with the pre-treatment assessment (baseline) by the BLE. Only data from the first 8-week phase will be taken into account. The No-Treatment control group after treatment will not be pooled for the primary endpoint.

The effectiveness of TEOSYAL® RHA Redensity will be demonstrated if:

- The responder rate for subjects treated with TEOSYAL® RHA Redensity is statistically superior to the responder rate for the No-Treatment control , and;
- The responder rate for subjects treated with TEOSYAL® RHA Redensity is $\geq 70\%$, and;
- The difference between the responder rate for subjects treated with TEOSYAL® RHA Redensity and the No-Treatment group is ≥ 50 points.

9.1.2 Secondary Endpoints

Statistical inference tests will be performed using two-sided tests, with a 0.05 significance level. Data will be summarized descriptively. For the Secondary Endpoints, like for the Primary Endpoint, only data from the first 8 week phase will be taken into account, and will compare TEOSYAL® RHA Redensity to No-Treatment (the No-Treatment control group after treatment will not be pooled for the secondary endpoints):

- **FACE-Q** at Week 4 and Week 8 after initial or touch-up treatment.
- Proportion of subjects with a Global Aesthetic “improved” or “much improved”, as assessed by **subject** at Week 4 and Week 8 after initial or touch-up treatment, using the 5-grade Global Aesthetic Improvement (**GAI**) scale.
- Proportion of subjects with a Global Aesthetic “improved” or “much improved”, as assessed by **BLE** at Week 8 after initial or touch-up treatment, using the 5-grade Global Aesthetic Improvement (**GAI**) scale.
- Proportion of subjects “satisfied” or “very satisfied” at Week 8 after initial or touch-up treatment, using the 5-point scale assessing **Subject Satisfaction** with study treatment.

9.1.3 Exploratory Endpoints

For the following Exploratory Endpoints, like for the Primary Endpoint, only data from the first 8 week phase will be taken into account and will compare TEOSYAL® RHA Redensity to No-Treatment (the No-Treatment control group after treatment will not be pooled for these exploratory endpoints):

- Proportion of subjects with ≥ 1 -grade improvement from pre-treatment on the **PR-SRS** as assessed by the **Treating Investigator**, at Week 4 and Week 8 after initial or touch-up treatment, compared with the pre-treatment assessment (baseline) by the Treating Investigator.
- Proportion of subjects with ≥ 1 -grade improvement from pre-treatment on the **PR-SRS**, as evaluated by the Independent Photographic Reviewers (**IPR**) at Week 8 after initial or touch-up treatment, compared with the pre-treatment assessment (baseline) by the IPR. For a given subject to be considered a responder, at least 2 of the 3 readers must have confirmed a 1-point improvement for that subject.
- Proportion of subjects with a Global Aesthetic “improved” or “much improved”, as assessed by **Treating Investigator** at Week 4 and Week 8 after initial or touch-up treatment, using the 5-grade Global Aesthetic Improvement (**GAI**) scale.
- Proportion of subjects with ≥ 1 -grade improvement from pre-treatment of dynamic perioral rhytids on the 1-4 Modified **Glogau** classification of wrinkling as assessed by the **BLE** at

Week 8 after initial or touch-up treatment, compared with the pre-treatment assessment (baseline) by the BLE.

- Proportion of subjects with ≥ 1 -grade improvement from pre-treatment of dynamic perioral rhytids on the 1-4 Modified **Glogau** classification of wrinkling as assessed by the **Treating Investigator** at Week 4 and Week 8 after initial or touch-up treatment, compared with the pre-treatment assessment (baseline) by the Treating Investigator.

For the following Exploratory Endpoints, unlike for the Primary and Secondary Endpoints, data from the TEOSYAL[®] RHA Redensity group and from the No-Treatment control group after treatment will be pooled (if deemed comparable).

- Proportion of subjects with a ≥ 1 -grade improvement based on the **PR-SRS** assessed by the **BLE** at Weeks 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment, compared with the pre-treatment assessment (baseline) by the BLE.
- Proportion of subjects with a ≥ 1 -grade improvement based on the **PR-SRS** assessed by the **Treating Investigator** at Weeks 4, 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment, compared with the pre-treatment assessment (baseline) by the Treating Investigator.
- Proportion of subjects with a ≥ 1 -grade improvement, based on the **PR-SRS** as evaluated by the Independent Photographic Reviewers (**IPR**) at Week 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment, compared with the pre-treatment assessment (baseline) by the IPR. For a given subject to be considered a responder, at least 2 of the 3 readers must have confirmed a 1-point improvement for that subject
- Proportion of subjects with ≥ 1 -grade improvement of their dynamic perioral rhytids on the 1-4 Modified **Glogau** classification of wrinkling as assessed by the **BLE** at Week 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment, compared with the pre-treatment assessment (baseline) by the BLE.
- Proportion of subjects with ≥ 1 -grade improvement of dynamic perioral rhytids on the 1-4 Modified **Glogau** classification of wrinkling as assessed by the **Treating Investigator** at Week 4, 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment, compared with the pre-treatment assessment (baseline) by the Treating Investigator.
- **FACE-Q** at Week 4, 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment
- Proportion of subjects with a Global Aesthetic “improved” or “much improved”, as assessed by **subjects** at Week 4, 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment, using the 5-grade Global Aesthetic Improvement (**GAI**) scale.
- Proportion of subjects with a Global Aesthetic “improved” or “much improved”, as assessed by **Treating Investigators** at Week 4, 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment, using the 5-grade Global Aesthetic Improvement (**GAI**) scale.
- Proportion of subjects with a Global Aesthetic “improved” or “much improved”, as assessed by **BLE** at Week 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment, using the 5-grade Global Aesthetic Improvement (**GAI**) scale.
- **Subject satisfaction** at Weeks 4, 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment, using the 5-point scale assessing subjects’ satisfaction with study treatment.
- Proportion of subjects with a **natural look and feel** ≥ 7 assessed by subjects at Week 4, 8, 12, 16, 24, 36, and 52 after initial or touch-up treatment, using an 11-point scale.

9.2 Safety Analyses

Safety data will be presented as listings and summary tables based on the SAFT Population (unless otherwise specified).

9.2.1 Adverse Events (AEs)

Safety outcomes will be incidence rate of AEs, including UADEs, types of AEs and relationship to study treatment (i.e., Treatment-Emergent Adverse Events [TEAEs]; Treatment-Related-Adverse Events [TRAEs]). TEAEs will include all reported AE since the time of informed consent. Any AEs that occur in the No-Treatment control group since the time of informed consent will be considered to be TEAEs. TRAEs will include all reported AEs that were deemed by the Treating Investigator to be possibly, probably or definitely related to study treatment.

Safety data will be tabulated with descriptive group statistics (mean, standard deviation, minimum, maximum). Severity and relationship to study treatment will be assessed.

AEs will be coded using MedDRA.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9.3 General Statistical Considerations

9.3.1 Statistical Testing

For specific information regarding the statistical tests to be used in this study, please refer to [REDACTED]. Statistical testing will be conducted using parametric and non-parametric processes as appropriate. Continuous variables that are normally distributed will be tested using the Student t-test, while testing will be conducted with the Mann-Whitney test if not normally distributed. Normality of the observed distribution will be confirmed using a Shapiro-Wilk test. Quantitative (i.e., nominal/categorical) variables in 2x2 tables will be tested using Fisher test. For larger tables (i.e., more than 2x2), Chi-2 test will be used if expected cell counts are all ≥ 5 .

All tests will be performed on a two-sided basis. A p-value of less than 5% will be considered statistically significant. First level risk error for secondary criteria will not be adjusted for multiplicity.

9.3.2 Comparison of Treatment Groups

Comparisons will be made between TEOSYAL[®] RHA Redensity and the control.

9.3.3 Descriptive Statistics

Descriptive statistics (i.e., frequency and percent) will be calculated for each treatment group. Quantitative variables will be presented by way of number of observations, number of missing values, mean, standard deviation, extreme values (minimum and maximum), median, and 95% confidence interval. Categorical data will be presented by way of number of observations, number of missing values, and for each observed category, the number of occurrences and its corresponding percentage.



9.3.5 Discontinuation and Drop-Outs

A dropout rate of up to 20% is assumed. Dropouts will not be replaced. All available data from dropouts will be included in the ITT analysis. The disposition of subjects will summarize the number of subjects enrolled and discontinued.

9.3.6 Multiple Comparisons

No methods will be used to accommodate multiplicity (unless otherwise specified).

9.3.7 Multicenter Data

The data will be pooled across centers for analysis. Additionally, data for each center will be provided in data listings.

9.3.8 Pooling of Data from US and Canadian Sites

In order to establish if safety and efficacy data from the the US and Canada can be combined, homogeneity of various baseline characteristics across the two countries will be explored (i.e., age, BMI, smoking history, alcohol history, sun exposure, and surgical/procedure history*).

** Surgical/procedure history limited to any previous facial and/or cosmetic surgery/procedures (e.g., facial aesthetic procedures such as laser/toxin/filler, rhytidectomy, blephrospasm, dental surgery, breast enhancement, etc.).*

Ethnicity, race and Fitzpatrick Skin Type do not need to be proportionately balanced between US sites and Canadian sites; however, the predefined minimal sample of subjects with Fitzpatrick Skin Types IV, V and VI must still be obtained in the subject population overall.

Testing will be performed with the null hypotheses being the absence of differences between the US and Canada. All observed two-sided p-values must be >0.05 to pool data; if the two-sided p-value is ≤ 0.05 , data collected from subjects of both countries will not be pooled unless further argumentation could be provided to support such pooling. Percentages of each characteristic will be compared using a Fischer's exact test, and continuous data will be compared using a Student t-test (or Mann-Whitney test if not normally distributed).

9.3.9 Visit Windows



9.3.10 Dates

Partial dates will be imputed to the lowest available element of time (e.g., month or year). Missing dates will not be imputed. In case of adverse events duration, if the month is missing, the 15 of the month will be used in the calculation of the duration while the 01 of July will be used in case of a missing year.

9.3.11 Interim Analysis

There will be no interim efficacy analysis.

9.3.12 Outliers

No method to process outliers will be used. Data will be analyzed as reported in the database.

9.3.13 Software Documentation

All summaries and statistical analyses will be performed using SAS® 9.3 or higher.

Table 1: Summary of Data				
Category	Sub-category	Value 1	Value 2	Value 3
A	A.1	10	20	30
A	A.2	15	25	35
B	B.1	20	30	40
B	B.2	25	35	45
C	C.1	30	40	50
C	C.2	35	45	55
D	D.1	40	50	60
D	D.2	45	55	65

Category	Item	Value	Unit	Notes
Food	Apples	120	kg	
Food	Bananas	80	kg	
Food	Oranges	150	kg	
Food	Pears	90	kg	
Food	Apples	110	kg	
Food	Bananas	70	kg	
Food	Oranges	140	kg	
Food	Pears	85	kg	
Food	Apples	100	kg	
Food	Bananas	60	kg	
Food	Oranges	130	kg	
Food	Pears	75	kg	
Food	Apples	90	kg	
Food	Bananas	50	kg	
Food	Oranges	120	kg	
Food	Pears	65	kg	
Food	Apples	80	kg	
Food	Bananas	40	kg	
Food	Oranges	110	kg	
Food	Pears	55	kg	
Food	Apples	70	kg	
Food	Bananas	30	kg	
Food	Oranges	100	kg	
Food	Pears	45	kg	
Food	Apples	60	kg	
Food	Bananas	20	kg	
Food	Oranges	90	kg	
Food	Pears	35	kg	
Food	Apples	50	kg	
Food	Bananas	10	kg	
Food	Oranges	80	kg	
Food	Pears	25	kg	
Food	Apples	40	kg	
Food	Bananas	5	kg	
Food	Oranges	70	kg	
Food	Pears	15	kg	
Food	Apples	30	kg	
Food	Bananas	0	kg	
Food	Oranges	60	kg	
Food	Pears	10	kg	
Food	Apples	20	kg	
Food	Bananas	0	kg	
Food	Oranges	50	kg	
Food	Pears	5	kg	
Food	Apples	10	kg	
Food	Bananas	0	kg	
Food	Oranges	40	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	30	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	20	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	10	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	
Food	Pears	0	kg	
Food	Apples	0	kg	
Food	Bananas	0	kg	
Food	Oranges	0	kg	

██████████	██████████	██████████	██████████	██████████
██████████	██████████	██████████	██████████	██████████

██████████	██████████	██████████	██████████	██████████
------------	------------	------------	------------	------------



[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

EFFICACY ANALYSIS

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED] [REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED] [REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED] [REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED] [REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]				

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

SAFETY ANALYSES

[REDACTED]				
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]				
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

APPENDIX B: STATISTICAL TABLES

[illegible]

[illegible]

[illegible]

[REDACTED]				
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]				
[REDACTED]				

[illegible]

	1	2	3	4
1	0	0	0	0
2	0	0	0	0
3	0	0	0	0
4	0	0	0	0
5	0	0	0	0
6	0	0	0	0
7	0	0	0	0
8	0	0	0	0
9	0	0	0	0
10	0	0	0	0
11	0	0	0	0
12	0	0	0	0
13	0	0	0	0
14	0	0	0	0
15	0	0	0	0
16	0	0	0	0
17	0	0	0	0
18	0	0	0	0
19	0	0	0	0
20	0	0	0	0
21	0	0	0	0
22	0	0	0	0
23	0	0	0	0
24	0	0	0	0
25	0	0	0	0
26	0	0	0	0
27	0	0	0	0
28	0	0	0	0
29	0	0	0	0
30	0	0	0	0
31	0	0	0	0
32	0	0	0	0
33	0	0	0	0
34	0	0	0	0
35	0	0	0	0
36	0	0	0	0
37	0	0	0	0
38	0	0	0	0
39	0	0	0	0
40	0	0	0	0
41	0	0	0	0
42	0	0	0	0
43	0	0	0	0
44	0	0	0	0
45	0	0	0	0
46	0	0	0	0
47	0	0	0	0
48	0	0	0	0
49	0	0	0	0
50	0	0	0	0
51	0	0	0	0
52	0	0	0	0
53	0	0	0	0
54	0	0	0	0
55	0	0	0	0
56	0	0	0	0
57	0	0	0	0
58	0	0	0	0
59	0	0	0	0
60	0	0	0	0
61	0	0	0	0
62	0	0	0	0
63	0	0	0	0
64	0	0	0	0
65	0	0	0	0
66	0	0	0	0
67	0	0	0	0
68	0	0	0	0
69	0	0	0	0
70	0	0	0	0
71	0	0	0	0
72	0	0	0	0
73	0	0	0	0
74	0	0	0	0
75	0	0	0	0
76	0	0	0	0
77	0	0	0	0
78	0	0	0	0
79	0	0	0	0
80	0	0	0	0
81	0	0	0	0
82	0	0	0	0
83	0	0	0	0
84	0	0	0	0
85	0	0	0	0
86	0	0	0	0
87	0	0	0	0
88	0	0	0	0
89	0	0	0	0
90	0	0	0	0
91	0	0	0	0
92	0	0	0	0
93	0	0	0	0
94	0	0	0	0
95	0	0	0	0
96	0	0	0	0
97	0	0	0	0
98	0	0	0	0
99	0	0	0	0
100	0	0	0	0

rhytidectomy

v.1.0; 30-Nov-2017

Category	Value
Category 1	Value 1
Category 2	Value 2
Category 3	Value 3
Category 4	Value 4
Category 5	Value 5
Category 6	Value 6
Category 7	Value 7
Category 8	Value 8
Category 9	Value 9
Category 10	Value 10
Category 11	Value 11
Category 12	Value 12
Category 13	Value 13
Category 14	Value 14
Category 15	Value 15
Category 16	Value 16
Category 17	Value 17
Category 18	Value 18
Category 19	Value 19
Category 20	Value 20
Category 21	Value 21
Category 22	Value 22
Category 23	Value 23
Category 24	Value 24
Category 25	Value 25
Category 26	Value 26
Category 27	Value 27
Category 28	Value 28
Category 29	Value 29
Category 30	Value 30
Category 31	Value 31
Category 32	Value 32
Category 33	Value 33
Category 34	Value 34
Category 35	Value 35
Category 36	Value 36
Category 37	Value 37
Category 38	Value 38
Category 39	Value 39
Category 40	Value 40
Category 41	Value 41
Category 42	Value 42
Category 43	Value 43
Category 44	Value 44
Category 45	Value 45
Category 46	Value 46
Category 47	Value 47
Category 48	Value 48
Category 49	Value 49
Category 50	Value 50
Category 51	Value 51
Category 52	Value 52
Category 53	Value 53
Category 54	Value 54
Category 55	Value 55
Category 56	Value 56
Category 57	Value 57
Category 58	Value 58
Category 59	Value 59
Category 60	Value 60
Category 61	Value 61
Category 62	Value 62
Category 63	Value 63
Category 64	Value 64
Category 65	Value 65
Category 66	Value 66
Category 67	Value 67
Category 68	Value 68
Category 69	Value 69
Category 70	Value 70
Category 71	Value 71
Category 72	Value 72
Category 73	Value 73
Category 74	Value 74
Category 75	Value 75
Category 76	Value 76
Category 77	Value 77
Category 78	Value 78
Category 79	Value 79
Category 80	Value 80
Category 81	Value 81
Category 82	Value 82
Category 83	Value 83
Category 84	Value 84
Category 85	Value 85
Category 86	Value 86
Category 87	Value 87
Category 88	Value 88
Category 89	Value 89
Category 90	Value 90
Category 91	Value 91
Category 92	Value 92
Category 93	Value 93
Category 94	Value 94
Category 95	Value 95
Category 96	Value 96
Category 97	Value 97
Category 98	Value 98
Category 99	Value 99
Category 100	Value 100

[REDACTED]			
[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]			
[REDACTED]			

[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]			
[REDACTED]			

[illegible]

[REDACTED]		
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]		
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]		

[REDACTED]		[REDACTED]	
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]		[REDACTED]	
[REDACTED]		[REDACTED]	

[illegible]

v.1.0; 30-Nov-2017

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[illegible][illegible][illegible]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]				
[REDACTED]				
[REDACTED]				
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]				

[REDACTED]				
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]				

[illegible][illegible]

[REDACTED]				
[REDACTED]				
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]				

[illegible]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[illegible][illegible][illegible]

[REDACTED]			
[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]			

[REDACTED]		
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]		

[REDACTED]	
[REDACTED]	
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	
[REDACTED]	

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[illegible]

[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

[illegible][illegible][illegible]

[illegible]

Country	Current government is responsible
Ukraine	100%
Poland	100%
Hungary	100%
Slovakia	100%
Czech Republic	100%
Romania	100%

Age Group	Don't know	No	Yes	Probably yes	Probably no
18-24	10%	10%	40%	20%	20%
25-34	10%	10%	30%	20%	30%
35-44	10%	10%	20%	30%	30%
45-54	10%	10%	20%	30%	30%
55-64	10%	10%	20%	40%	20%

[illegible]

Age Group	Very important	Important	Somewhat important	Not important	Don't know
18-24	45%	35%	15%	5%	0%
25-34	40%	30%	20%	10%	0%
35-44	35%	25%	25%	15%	0%
45-54	30%	20%	30%	20%	0%
55-64	25%	15%	35%	25%	0%
65+	20%	10%	40%	30%	0%

Age Group	Very important	Important	Somewhat important	Not important	Don't know
18-24	~85%	~10%	~3%	~1%	~1%
25-34	~75%	~15%	~5%	~1%	~2%
35-44	~65%	~20%	~8%	~2%	~5%
45-54	~60%	~25%	~10%	~3%	~6%
55-64	~55%	~25%	~12%	~4%	~6%
65+	~50%	~25%	~15%	~5%	~7%

Page 63 of 66

[REDACTED]	
[REDACTED]	
[REDACTED]	[REDACTED]
[REDACTED]	
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

[REDACTED]

[illegible]